Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.44 |
| ▸ | MMP2 | P08253 | 8/20 | 0.40 |
| ▸ | MMP9 | P14780 | 8/20 | 0.40 |
| ▸ | MMP8 | P22894 | 8/20 | 0.40 |
| ▸ | MMP13 | P45452 | 8/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | NCF1 | P14598 | 2/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999887 | 1.00 | DGAT1 (0.44) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL18751726 | 0.93 | DGAT1 (0.48) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL18768886 | 0.91 | DGAT1 (0.45) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21099982 | 0.89 | DGAT1 (0.42) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL19704939 | 0.89 | DGAT1 (0.44) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21087464 | 0.86 | DGAT1 (0.53) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21099971 | 0.86 | DGAT1 (0.43) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL18751731 | 0.85 | DGAT1 (0.53) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21118070 | 0.85 | DGAT1 (0.54) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21087465 | 0.85 | DGAT1 (0.54) | DGAT1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | DGAT1 1239/4885MMP2 2692/4885MMP9 4828/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | DGAT1 1239/4885MMP2 2692/4885MMP9 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.